Clinical Trial Update: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant [Phase 3]

View source ↗

Summary

This entry notes that Acoramidis is being evaluated in a Phase 3 ACT-EARLY prevention trial in asymptomatic carriers of pathogenic TTR variants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Cardiomyopathy
• Amyloidosis
• Cardiomyopathy
• Polyneuropathy
• Transthyretin Amyloidosis

Drugs mentioned

• Acoramidis (acoramidis)

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Status: RECRUITING